Current Obstacles in Myeloma Management: Debating the Evidence

Registration

Live Event Registration Live Webinar Registration

Join us on Friday, December 6, 2019, for a CME-certified Friday Satellite Symposium preceding the 61st American Society of Hematology (ASH) Annual Meeting and Exposition.

Current Obstacles in Myeloma Management: Debating the Evidence

Friday, December 6, 2019

7:00 AM – 11:00 AM (Eastern Time)
Hyatt Regency Orlando
Room: Regency T-V
9801 International Drive
Orlando, Florida 32819

7:00 AM – 8:00 AM  Registration and Breakfast
8:00 AM – 11:00 AM  Scientific Program


There is no fee for attending this symposium, however seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

If you are unable to join us in Orlando, you don’t have to miss out: we’ll be livecasting this symposium. When registering, please indicate whether you will be attending the symposium or participating via the livecast.  

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma (MM).

Program Overview

The clinical MM arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The availability of new agents (since 2006, 11 new MM drugs have been approved!) has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients. Treatment advances have improved median survival; nevertheless, prognosis remains poor for some patients—a clinical reality that reflects the heterogeneity of MM. To achieve the best possible outcomes, clinicians must apply risk-adapted treatment strategies, though the implementation and timing of these strategies remains controversial. Preventing relapse is another ongoing challenge for clinicians. New agents and combinations have expanded treatment options, but utilizing them to best effect requires the ability to personalize treatment to each patient. Ultimately, clinicians need to prepare a plan for eventual relapse by being aware of new (and imminent) agents and of clinical trials of potential benefit. Increasingly, newer drugs—those currently indicated for relapsed disease—are also being used in the frontline setting, which may influence what options remain at relapse. This symposium will follow a debate format and feature audience polling relating to the proffered arguments, as well as panel discussions.

Learning Objectives

At the conclusion of this activity, participants should be better able to:
  • Describe the benefits and limitations of treatment of patients with SMM
  • Develop individualized treatment plans for MM patients based on risk and cytogenetic and genomic data
  • Evaluate emerging data regarding the optimal timing and approach to high-dose melphalan therapy with autologous stem cell transplantation based on minimal residual disease status
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence

Faculty

Paul G. Richardson, MD—Program Co-Chair
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB—Program Co-Chair
Mayo Clinic
Scottsdale, Arizona

Faith E. Davies, MBBCh, MD, MRCP, FRCPath
Perlmutter Cancer Center at New York University Langone Health
New York, New York

Rafael Fonseca, MD
Mayo Clinic
Phoenix, Arizona

Amrita Y. Krishnan, MD
City of Hope Medical Center
Duarte, California

Saad Z. Usmani, MD
Levine Cancer Institute
Charlotte, North Carolina

Agenda

8:00 AM
 
Introduction and Overview
Paul G. Richardson, MD and A. Keith Stewart, MBChB—Program Co-Chairs
8:15 AM Debate 1: Should Smoldering Myeloma Be Treated?
For Treatment
  Saad Usmani, MD
• Against Treatment
  Rafael Fonseca, MD
8:45 AM
 
Debate 2: Can We Apply Risk-Adapted Therapy to Multiple Myeloma Patients?
Yes, We Can
  Faith E. Davies, MBBCh, MD, MRCP, FRCPath
No, We Can’t
  Keith Stewart, MBChB
9:15 AM
 
Questions and Answers
All
9:35 AM
 
Debate 3: Transplant (Early) or No Transplant (Delayed)?
For Transplant (Early)
  Amrita Y. Krishnan, MD
No Transplant (Delayed)
  Paul G. Richardson, MD
10:05 AM
 
Debate 4: Immunotherapy: Up Front or At Relapse?
Use Up Front
  Saad Usmani, MD
Use at Relapse
  Faith E. Davies, MBBCh, MD, MRCP, FRCPath
10:35 AM
 
Questions and Answers
All

Join the discussion on twitter: #RMELiveMM

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Access Statement

RedMedEd complies fully with the legal requirements of the Americans With Disabilities Act. If you are in need of special accommodation, please indicate your need in writing or contact Karen Tenaglia at 610.251.6841 or ktenaglia@redmeded.com.

Jointly provided by
   

Support for this activity has been provided through educational grants from Adaptive Biotechnologies; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Sanofi Genzyme.